BIM Stock Overview
Develops and markets in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for BIM from our risk checks.
My Notes
Capture your thoughts, links and company narrative
bioMérieux S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €102.20 |
| 52 Week High | €111.50 |
| 52 Week Low | €88.25 |
| Beta | 0.23 |
| 1 Month Change | 3.55% |
| 3 Month Change | -6.15% |
| 1 Year Change | 1.19% |
| 3 Year Change | -17.75% |
| 5 Year Change | 27.19% |
| Change since IPO | 922.00% |
Recent News & Updates
Slowing Rates Of Return At bioMérieux (EPA:BIM) Leave Little Room For Excitement
Dec 10
Is bioMérieux (EPA:BIM) Using Too Much Debt?
Nov 01Is There An Opportunity With bioMérieux S.A.'s (EPA:BIM) 31% Undervaluation?
Oct 14bioMérieux S.A.'s (EPA:BIM) Popularity With Investors Is Under Threat From Overpricing
Sep 26bioMérieux S.A. (EPA:BIM) Just Reported Interim Earnings: Have Analysts Changed Their Mind On The Stock?
Sep 08Recent updates
Slowing Rates Of Return At bioMérieux (EPA:BIM) Leave Little Room For Excitement
Dec 10Is bioMérieux (EPA:BIM) Using Too Much Debt?
Nov 01Is There An Opportunity With bioMérieux S.A.'s (EPA:BIM) 31% Undervaluation?
Oct 14bioMérieux S.A.'s (EPA:BIM) Popularity With Investors Is Under Threat From Overpricing
Sep 26bioMérieux S.A. (EPA:BIM) Just Reported Interim Earnings: Have Analysts Changed Their Mind On The Stock?
Sep 08Return Trends At bioMérieux (EPA:BIM) Aren't Appealing
Aug 03bioMérieux S.A.'s (EPA:BIM) Price In Tune With Earnings
May 30Investors Met With Slowing Returns on Capital At bioMérieux (EPA:BIM)
Apr 18bioMérieux's (EPA:BIM) Conservative Accounting Might Explain Soft Earnings
Mar 31bioMérieux S.A. Just Missed Earnings - But Analysts Have Updated Their Models
Mar 17These 4 Measures Indicate That bioMérieux (EPA:BIM) Is Using Debt Reasonably Well
Mar 15bioMérieux S.A.'s (EPA:BIM) Price In Tune With Earnings
Jan 27bioMérieux (EPA:BIM) Has More To Do To Multiply In Value Going Forward
Jan 06Shareholder Returns
| BIM | FR Medical Equipment | FR Market | |
|---|---|---|---|
| 7D | 0.1% | 0.003% | -1.7% |
| 1Y | 1.2% | 23.6% | -4.8% |
Return vs Industry: BIM underperformed the French Medical Equipment industry which returned 23.6% over the past year.
Return vs Market: BIM exceeded the French Market which returned -4.8% over the past year.
Price Volatility
| BIM volatility | |
|---|---|
| BIM Average Weekly Movement | 2.6% |
| Medical Equipment Industry Average Movement | 6.7% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in FR Market | 9.7% |
| 10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: BIM has not had significant price volatility in the past 3 months compared to the French market.
Volatility Over Time: BIM's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1963 | 13,696 | Pierre Boulud | www.biomerieux.com |
bioMérieux S.A. develops and markets in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers CHROMID RANGE, a chromogen culture media; RAPIDEC CARBA NP biochemical test for the detection of carbapenemaseproducing bacteria; air, surface, and water monitoring systems; BACT/ALERT VIRTUO BACT/ALERT 3D, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction (PCR) system; BIOFIRE SPOTFIRE Lowplex PCR point-of-care system; VITEK MS, a mass spectrometry system; VITEK 2, an automated Identification and antimicrobial susceptibility testing (AST) system; API RANGE standardized ID strips; VITEK REVEAL Rapid AST system; ETEST Gradient method on culture media; BIOMERIEUX EPISEQ CS whole genome sequencing solution for epidemiologic monitoring; and VIDASB·R·A·H·M·S PCTTM, a specific marker of severe bacterial infections/sepsis. It also provides Biomérieux vision suite, a software that provides actionable information to support diagnosis and clinical decision making; culture media and associated instruments; ARGENE Monoplex PCR tests; NUCLISENS ranges, a product for automation of the molecular biology laboratory and extraction; EMAG system For DNA and RNA extraction; ESTREAM, an automated preparation station for samples to process PCR tests; GENE-UP and VERIFLOW ranges for detection of microorganisms for the food industry.
bioMérieux S.A. Fundamentals Summary
| BIM fundamental statistics | |
|---|---|
| Market cap | €12.06b |
| Earnings (TTM) | €411.30m |
| Revenue (TTM) | €3.81b |
29.3x
P/E Ratio3.2x
P/S RatioIs BIM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIM income statement (TTM) | |
|---|---|
| Revenue | €3.81b |
| Cost of Revenue | €1.69b |
| Gross Profit | €2.12b |
| Other Expenses | €1.71b |
| Earnings | €411.30m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.49 |
| Gross Margin | 55.72% |
| Net Profit Margin | 10.81% |
| Debt/Equity Ratio | 10.1% |
How did BIM perform over the long term?
See historical performance and comparisonDividends
0.8%
Current Dividend Yield24%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 01:25 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
bioMérieux S.A. is covered by 35 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Armelle Moulin | AlphaValue |
| Gaurav Jain | Barclays |
| Samuel England | Berenberg |